Figure 1. Most researched therapy areas for SLR/NMA/MA
Figure 2. Top 5 countries that published SLR/NMA/MA
Figure 3. Use of reporting guidelines
Figure 4. Impact factors of journals
In summary, SR/MA and NMA’s are promising to inform comparative effectiveness research in the presence of multiple treatments, however, clinical question should be developed with input from a clinical expert with expertise in therapeutic area, statistician and relevant contributors.
Prospective registration of such studies helps to enhance transparency, reduces potential outcome reporting bias and helps to avoid duplication of reviews. This in turn helps to fulfill the underlying aim of ensuring that social-health care decisions are informed by good-quality evidence, in the public interest.
A high-quality SR/MA or NMA should include a study protocol written in advance and include all details that are transparent, reproducible, adhering to PRISMA reporting guidelines and intended research plan to help avoid bias.
Lastly, as such studies are generally very time-consuming and costly to carry out, the editors and peer-reviewers of the registry should provide quick feedback to avoid duplicate or similar reviews' undertaken and any reporting biases.
Indegene is a technology-led healthcare solutions provider and all the authors have no COI.